PRODUCT
PIPELINE
PRODUCT PIPELINE
Just the Start for
Formulation Development
We have developed a range of current products with FDA approval for clinical trials, aiming to make drug administration easier and more efficient.
Levellor® Insulin
Pre-Clinical
The pre-clinical trial for HypoSpray Insulin Delivery has yielded promising outcomes, demonstrating that it provides dose-dependent glucose control with verifiable insulin levels compared to the traditional method of insulin injection. A Healthy Volunteer Clinical study established safety (Clinicaltrials.gov: NCT04857320 ).
In a strategic move to bring this innovative solution to market, we have partnered with InsuLife AS, who have taken an option on the HSP Insulin. This partnership aims to commercialize the product, making it more accessible to patients in need of effective diabetes management solutions.
The collaboration with InsuLife AS and the encouraging results from the studies to date signify a major advancement in diabetes care.
EpiSpray® Epinephrine
Pre-Clinical
HypoSpray Pharma's clinical program for Epinephrine includes a clinical pharmacology study to assess the safety, tolerability, and pharmacokinetics of HypoSpray® Epinephrine compared to intravenous epinephrine.
This study is designed to provide data to support a New Drug Application (NDA) submission to the FDA. Additionally, HypoSpray Pharma is conducting a clinical trial to assess the efficacy of HypoSpray® Epinephrine in treating anaphylaxis in patients who are allergic to food or insect stings. This trial is designed to support the NDA submission. The data collected from both studies will be used to support the safety and efficacy of HypoSpray® Epinephrine for the treatment of anaphylaxis.
Testagen® Testosterone
Pre-Clinical
Currently enrolling for dosing and transference studies for its first product, Testagen® spray-on Testosterone. The testosterone market exceeds $2 billion annually, of which a single gel product represents more than 50%—however, this gel product can be transferred on contact with another person up to 24 hours after dosing. In contrast, HYPOSPRAY Pharma’s Testagen® product speeds absorption and reduces transference risk to 20 minutes or less.
Spray-on testosterone offers a massive advantage over the incumbent gel product with dramatic lifestyle improvement for patients who are currently unable to dress quickly, exercise, shower, or have intimate relations for up to eight hours after application to avoid washing off or transferring the gel to another person.
​
DicloMist® Diclofenac Sodium (NSAID)
Pre-Clinical
HYPOSPRAY Pharma is developing transdermal variants of Diclofenac, Ibuprofen and Acetaminophen, which will enable significantly lower dosages to be administered without loss of pain relief, while reducing pain medication side effects such as nausea, improving safety characteristics through mitigation of liver toxicity due to lowered doses, and easier administration to major sub-segments such as pediatrics.